Rural-Urban Disparities in Heart Failure and Liver Cirrhosis Hospitalizations: A National Inpatient Sample Database Analysis (2016–2022) Authors: Farah Yasmin, Yusra Mashkoor, Maryam Shahryar, Ahmad Barbour, Muhammad Sohaib Asghar, M. Chadi Alraies Published: 2026 ABSTRACT Heart failure and cirrhosis interplay predisposes patients to increased inpatient morbidity, acute decompensation, renal injury, infection, procedural complications, prolonged hospitalizations, and healthcare costs. In this retrospective observational study, we analyzed data from the Nationwide Inpatient Sample spanning 2016 to 2022 to assess rural-urban disparities and temporal trends in adult patients hospitalized with concurrent HF and liver cirrhosis in the U.S. Validated International Classification of Diseases, 10th Revision codes were used to identify these patients. A total of 498,539 hospitalizations (weighted >2.49 million) met inclusion criteria, of which 14.9% occurred in non-metropolitan hospitals and 85.1% in metropolitan hospitals. In-hospital mortality was higher in rural settings (8.0% vs. 7.3%), with slightly longer hospital stays in urban settings that incurred a greater financial burden, with higher inflation-adjusted costs ($24,026 vs. $20,948). These results were consistent with propensity-matching. The study concludes that strategies to improve regional healthcare access and equity in complex multisystem disease management are needed. Heart failure (HF) affects over 6.5 million adults in the United States (U.S.) and remains a leading cause of hospitalization and healthcare expenditure.1) Concurrently, liver cirrhosis accounts for over 34,000 annual deaths in the U.S., with hospitalizations rising by nearly 65% over the last two decades.2) When coexisting, HF and cirrhosis create a complex clinical scenario characterized by overlapping hemodynamic derangements, neurohormonal activation, systemic inflammation, and metabolic dysregulation.34) Cirrhosis contributes to systemic vasodilation, portal hypertension, and neurohormonal activation, while cirrhotic cardiomyopathy and systemic inflammation further impair cardiac reserve. Conversely, HF exacerbates hepatic congestion and ischemic injury, accelerating portal hypertension and liver dysfunction. This interplay predisposes patients to increased inpatient morbidity, higher rates of acute decompensation, renal injury, and infection, translating into higher inpatient morbidity, increased procedural complications, prolonged hospitalizations, and elevated healthcare costs compared with either condition alone.5) Despite these outcomes, urbanization-related disparities in this population remain underexplored. Prior literature shows that rural patients with chronic diseases often face delayed access to specialty care, limited procedural interventions, and worse clinical outcomes.6) While socioeconomic and racial disparities in HF and cirrhosis have been studied, the influence of geographic location, particularly rural vs. urban settings, on outcomes in patients with both HF and cirrhosis has not been comprehensively investigated.78) Addressing these gaps is essential for equitable healthcare planning and targeted policy implementation. In this retrospective observational study, we analyzed data from the Nationwide Inpatient Sample (NIS) spanning 2016 to 2022 to assess rural-urban disparities and temporal trends in adult patients hospitalized with concurrent HF and liver cirrhosis in the U.S. Patient identification was based on validated International Classification of Diseases, 10th Revision (ICD-10) codes for both HF and liver cirrhosis. Records of patients younger than 18 years or with missing key demographic or clinical information were excluded. National-level estimates were generated using hospital discharge weights as recommended by the Healthcare Cost and Utilization Project (HCUP).9) Central (>1 million population), fringe (<1 million), medium (>250,000) and small (<250,000) were classified as metropolitan/urban areas while micropolitan (<50,000) and non-core (<10,000) were categorized as non-metropolitan/rural areas in accordance with National Center for Health Statistics urban-rural classification. Descriptive statistics were used to characterize the cohort, including frequencies, percentages, means, and standard deviations. Baseline sociodemographic and hospital-related variables were compared between rural and urban groups using odds ratios. Multivariate logistic regression models examined in-hospital outcomes adjusting for key covariates, including patient demographics (age, sex, race), Charlson Comorbidity Index (CCI), hospital-level characteristics (bed size, teaching status, urban/rural location, ownership), and indicators of socioeconomic status (ZIP code level income quartiles and insurance type). Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) were reported for all outcomes of interest. Covariate balance was assessed using standardized differences and global balance metrics (pseudo R2, mean standardized bias, Rubin’s B and R statistics). A standardized difference <0.1, mean/median bias <10%, Rubin’s B <25, and Rubin’s R between 0.5–2.0 were considered indicative of adequate balance between the groups. Propensity-matching using nearest neighbor method was applied to compare groups after considering residual confounding. Trend analyses were conducted using the Cochran-Armitage test to evaluate the primary outcome i.e., in-hospital mortality, with interaction analysis applied to examine subgroup effects. The Jonckheere-Terpstra test assessed ordered differences in secondary outcomes, including hospital length of stay (LOS) and inflation-adjusted costs. All analyses incorporated survey design elements—discharge weights and hospital strata—based on the HCUP guidelines to ensure national representation. For cost analysis, hospital charges were converted into actual costs using cost-to-charge ratios and adjusted for inflation using the U.S. Medical Care Consumer Price Index, standardized to 2022 values. A total of 498,539 hospitalizations (weighted >2.49 million) met inclusion criteria (Supplementary Figure 1), of which 14.9% (n=74,348) occurred in non-metropolitan hospitals and 85.1% (n=424,191) in metropolitan hospitals. Patients in rural hospitals were slightly younger (mean age: 65.0 vs. 65.1 years; p=0.018), more frequently female (42.2% vs. 40.9%; p<0.001), and disproportionately White (82.0% vs. 60.3%; p<0.001). Socioeconomic disparities were pronounced, with rural patients more likely to reside in zip codes from the lowest median household income quartile (59.8% vs. 32.1%; p<0.001). Emergency department admissions were less frequent in rural hospitals (65.7% vs. 84.1%; p<0.001), while elective admissions occurred more often (9.8% vs. 5.6%; p<0.001), potentially reflecting barriers to timely acute care access (Supplementary Table 1). Yearly trends in admissions showed that urban hospitals had a higher patient volume from 2016 to 2019 (p<0.001), but this pattern reversed from 2020 to 2022, with rural hospitals seeing greater admissions (p<0.001). Additionally, comorbidities profile revealed that rural patients had significantly higher prevalence of diabetes (49.9% vs. 48.3%; p<0.001), hypothyroidism (18.7% vs. 16.8%; p<0.001), chronic obstructive pulmonary disease (38.4% vs. 32.8%; p<0.001), obstructive sleep apnea (15.4% vs. 14.3%; p<0.001), and moderate to severe liver disease (27.8% vs. 25.1%; p<0.001). In contrast, urban patients had a greater burden of hypertension (83.0% vs. 80.1%; p<0.001), dyslipidemia (40.4% vs. 38.7%; p<0.001), end-stage renal disease (14.7% vs. 10.8%; p<0.001), and amyloidosis (0.5% vs. 0.2%; p<0.001). Cardiovascular conditions also differed by setting. Coronary artery disease (CAD) was more prevalent in rural patients (43.4% vs. 41.5%; p<0.001), along with higher rates of non-ST-segment elevation myocardial infarction (5.0% vs. 4.3%; p<0.001), prior percutaneous coronary intervention (PCI) (9.5% vs. 8.8%; p<0.001), and coronary artery bypass grafting (CABG) (8.9% vs. 7.8%; p<0.001). However, urban patients had higher rates of implantable cardioverter-defibrillator placement (11.0% vs. 10.1%; p<0.001) (Supplementary Table 2). Importantly, rural hospitalizations for patients with concurrent HF and liver cirrhosis were associated with significantly worse outcomes and higher healthcare utilization compared to urban hospitalizations. In-hospital mortality was higher in rural settings (8.0% vs. 7.3%; p<0.001), however patients experienced longer average hospital stays (7.4 vs. 7.0 days; p<0.001) in urban settings. Additionally, urban hospitalizations incurred a greater financial burden, with higher mean hospital charges ($97,346.0 vs. $74,197.4; p<0.001) and inflation-adjusted costs ($24,026 vs. $20,948; p<0.001). Although a slightly higher proportion of rural patients were discharged to routine home care (43.6% vs. 43.5%; p<0.001), urban patients were marginally more likely to be transferred to intermediate or skilled nursing facilities (21.8% vs. 21.6%; p<0.001) and home health (as shown in Supplementary Table 3). Regarding in-hospital events and procedures, urban patients experienced higher rates of major bleeding (p=0.006), RBC transfusions (p<0.001), in-hospital cardiac arrest (p=0.046), acute venous thromboembolism (p<0.001), catheter ablation (p<0.001), tracheostomy (p<0.001), and mechanical circulatory support (p<0.001). Conversely, rural patients had higher rates of in-hospital PCI (p=0.001) and CABG (p=0.008) (Supplementary Table 2). Trends in age-adjusted mortality rates (AAMR) for patients hospitalized with HF and liver cirrhosis from 2016 to 2022 revealed notable fluctuations, with a pronounced increase observed in 2021—likely reflecting the impact of the coronavirus disease 2019 (COVID-19) pandemic. Over the study period, AAMRs showed an overall upward trajectory. Rural patients consistently exhibited higher AAMRs than their urban counterparts, with a markedly steeper annual percent change of 5.33, as opposed to 1.77 for urban patients and 2.34 for the overall population (Supplementary Figure 2A). Unadjusted in-hospital mortality rates also rose, especially from 2019 onward, peaking in 2021 likely due to the COVID-19 pandemic. The Cochran-Armitage test confirmed significantly higher in-hospital mortality among rural patients than urban patients (p<0.001) (Supplementary Figure 2B). Trends in mean hospital LOS, stratified by urbanization, are illustrated in Supplementary Figure 2C. The Jonckheere-Terpstra test indicated a statistically significant increase in LOS over time for both rural and urban patients (p<0.001 for each). Despite this parallel upward trend, LOS remained consistently longer for urban patients throughout the study period as shown in Supplementary Table 3. Similarly, inflation-adjusted hospital costs demonstrated a significant upward trend across both groups (p<0.001 for rural and urban patients), as shown in Supplementary Figure 2D. While costs increased over time in both settings, urban hospitalizations consistently incurred higher average expenses—from $23,711 vs. $20,504 in 2016 to $24,540 vs. $21,866 in 2022. These results were consistent with propensity-matching as showcased in Supplementary Table 3. Supplementary Table 4 summarizes the results of the multivariate regression analysis examining urbanization-related disparities in resource utilization and in-hospital mortality among patients with HF and liver cirrhosis. After adjusting for demographic, clinical, and hospital-level variables, rural hospitalization was independently associated with higher odds of in-hospital mortality (aOR, 1.116; 95% CI, 1.081 to 1.153; p<0.001). Additionally, rural patients had significantly shorter hospital stays (−0.408 days; 95% CI, −0.481 to −0.335; p<0.001) and lower hospitalization costs (−$1,573.3; 95% CI, −1,890.7 to −1,256.1; p<0.001), suggesting possible underutilization of inpatient services. They were also less likely to be discharged to skilled nursing facilities (aOR, 0.957; 95% CI, 0.937 to 0.978; p<0.001). While these findings may indicate underutilization of inpatient resources, alternative explanations such as differences in care goals and documentation practices, earlier discharges due to limited step-down care availability, or interhospital transfers to urban centers should also be considered. Importantly, transfers between rural and urban hospitals, which are not captured in the NIS, may have influenced these results and represent a key limitation. Predictors of in-hospital mortality for the overall cohort, as well as rural and urban subgroups, revealed that cardiac arrest, invasive mechanical ventilation, acute bowel ischemia, and hemodialysis were associated with the highest mortality risk, with all predictors reaching statistical significance (p<0.001) (Supplementary Figure 3). Before adjusting for covariates listed in Supplementary Table 4, mean bias across covariates was 25.2%, Pseudo R2=0.323, Rubin’s B=115.1 and Rubin’s R=0.56. After adjustment for confounders, mean bias decreased to 6.9%, Pseudo R2 dropped to 0.016, Rubin’s B was 30.1, and Rubin’s R was 0.95, indicating substantial improvement in covariate balance as shown in Supplementary Table 5. Supplementary Table 6 shows covariates using age and CCI used in propensity matching as continuous variables while rest of the categorical variables are addressed in Supplementary Figure 4. This nationwide analysis of the NIS database from 2016 to 2022 revealed substantial urbanization-related disparities in the clinical profile, healthcare resource utilization, and in-hospital outcomes of patients admitted with HF and liver cirrhosis. The higher mortality seen in rural settings, despite these patients being slightly younger and more likely female, may reflect delayed presentations, higher comorbidity burden, limited specialty services, and fragmented post-discharge care pathways.6) In our analysis, rural patients had significantly higher rates of comorbidities including diabetes mellitus, chronic obstructive pulmonary disease, and CAD, which may worsen the hemodynamic and metabolic interplay between HF and cirrhosis, potentially negating the survival advantage typically associated with younger age and female sex. Strategies to improve regional healthcare access and equity in complex multisystem disease management are urgently needed. Schematic representation illustrating the link of HF-liver cirrhosis and systems-based overlap is presented in Supplementary Figure 5. Nonetheless, our study has certain limitations. First, it relied on administrative ICD-10 coding, which is subject to potential misclassification. Second, the NIS captures only inpatient encounters, limiting the generalizability of results to outpatient populations or patients not requiring hospitalization. Third, as the NIS does not track interhospital transfers, such movements particularly from rural to urban facilities may influence LOS, cost, and mortality estimates. Future analyses using linked datasets, such as the National Readmissions Database, are warranted to address this limitation. Finally, although we observed a marked increase in mortality during the COVID-19 pandemic, further research is needed to delineate the pandemic’s direct and indirect effects on this high-risk population. The temporal trends may be distorted by the impact of COVID-19, which could differentially affect hospitalization patterns, mortality, and resource utilization over time.